All News
SAPHO Syndrome Revisted
SAPHO is an acronym that describes a constellation of findings (synovitis, acne, pustulosis, hyperostosis, and osteitis) that defines this rare syndrome.
Read ArticleRheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Read Article
Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee
The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.
Read ArticleFDA Says Cryotherapy Lacks Evidence, Poses Risks
Cryotherapy is a non-FDA approved treatment that has been promoted to treat post-athletic injury, osteoarthritis,rheumatoid arthritis, fibromyalgia, alzheimers, migraines, asthma, multiple sclerosis, etc. Cryotherapy may be as simple as ice packs on a localized portion of the body, such as the lower back, or may involve whole body cryotherapy.
Read Article
Cancer Risk Lower with TNF inhibitors in Rheumatoid Arthritis
Since the introduction of TNF inhibitors nearly 20 years ago, concerns over a potential associated cancer risk have abounded. The recent ACR RA treatment guidelines have addressed this recently, stating that patients with any solid tumor cancer or risk thereof should be treated as if they ha
Read ArticleAS Diagnosis Linked to CVD Risk
Prevalent patients with ankylosing spondylitis (AS) face a 30–50% increased risk of acute coronary, cerebrovascular, and thromboembolic events compared with the general population.
Read ArticleRheumNow Week in Review – 24 June 2016
Dr. Cush reviews highlights published this week at RheumNow.com.
Read Article
Predictors of Progression in Early Inflammatory Polyarthritis
A substantial, but unclear, percentage of patients presenting with new onset inflammatory polyarthritis (IP) will spontaneously remit, while others may persist and develop rheumatoid arthritis (RA).
Read ArticleEULAR 2016 Drug Safety Report
The EULAR Annual European Congress of Rheumatology meeting was held in London from June 8-11, 2016 and was well attended by thousands. This year’s meeting had over 2,000 poster displays, and the EULAR 2016 Congress presented new recommendations on the management of rheumatoid arthritis, spondyloarthritis, and fibromyalgia.
Read Article
Steroid Use in Early Rheumatoid Arthritis Associated with Fractures
The impact of systemic glucocorticoid exposure on fracture risk among new-onset rheumatoid arthritis (RA) was studied using administrative claims data detailing the treatments and outcomes of 42,127 newly diagnosed RA patients (between 2005-2012).
Read ArticleRheumNow Week in Review – 17 June 2016
Dr. Jack Cush reviews the news, reports and highlights from EULAR and the last 2 weeks from RheumNow.com.
Read ArticleEuropean Registries Show No Melanoma Risk with Biologics
The combined analysis of 130,315 rheumatoid arthritis patients from 11 European registries did not reveal an association between invasive (malignant) melanoma and the use of biologic therapies.
Read Article
No Increased Risk of Colitis Flares in Secukinumab Trials
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
Read ArticleEULAR: Tofacitinib Effective in Ankylosing Spondylitis
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
Read Article
IL-23 Inhibitor Effective in Crohn's Disease
Selective IL-23 inhibition has been touted to be the next great advance in the treatment of inflammatory bowel and psoriatic disease.
Read ArticleTB Management Questions
The following is a compilation of several frequently asked questions regarding tuberculosis (TB) testing or treatment in patients on a TNF inhibitor (TNFi) or other biologic agents.
Read ArticleSecukinumab Improves Patient-Reported Outcomes in Psoriatic Arthritis (FUTURE 1)
Secukinumab (Cosentyx) has recently been approved for use in ankylosing spondylitis and psoriatic arthritis; the latter largely based on the FUTURE 2 and the just reported FUTURE 1 clinical trial. FUTURE 1 demonstrates the efficacy and safety of secukinumab, with inital weekly intravenous loading, given monthly as a subcutaneous injection.
Read Article
Moderate Alcohol Intake While on Methotrexate Appears Prudent
Research presented at the annual British Society for Rheumatology conference revealed that rheumatoid arthritis patients who drink moderately while taking methotrexate appear to be at no greater risk for liver damage than nondrinkers.
Read Article
The RheumNow Week in Review – 6 May 2016
Watch Dr. Cush discuss the highlights from this week on RheumNow.com.
Read Article
Methotrexate Yields No Added Benefit in Etanercept Treated Psoriatic Arthritis Patients
Despite a paucity of clinical trial proof, methotrexate is often advocated or mandated to treat psoriatic arthritis. A recent comparison of clinical trials outcomes fails to show any added value when MTX is given to PsA patients taking etanercept.
Read Article